Stay updated on INOVATYON: Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the INOVATYON: Ovarian Cancer Clinical Trial page.

Latest updates to the INOVATYON: Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded related topics including Ovarian cancer and MedlinePlus Genetics, and removed the prior funding notice and an older revision tag (v3.4.1 }).SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding notice banner and a page revision indicator were added. A related topics entry for Ovarian cancer/MedlinePlus Genetics and the prior Revision: v3.4.0 were removed.SummaryDifference0.3%

- Check28 days agoChange DetectedAdded a Show glossary control and linked topics, including Ovarian cancer and MedlinePlus Genetics. Updated the page footer metadata to Revision: v3.4.0 and standardized capitalization of QC/FEAR Act labels, removing the older v3.3.4 variant.SummaryDifference0.2%

- Check35 days agoChange DetectedOvarian cancer topic and related genetics resources are removed from the page, reducing direct context for the study's focus and limiting quick access to condition-specific information. This may affect users' ability to understand the study's scope and locate related resources.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page's revision metadata updated from v3.3.3 to v3.3.4, a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page now displays an extensive Locations section with many sites across multiple countries, broadening visibility of study sites. The HHS Vulnerability Disclosure and several location subsections were removed in this revision.SummaryDifference2%

Stay in the know with updates to INOVATYON: Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INOVATYON: Ovarian Cancer Clinical Trial page.